Actual Medicinal Product (AMP) Zeffix 100mg tablets (Dowelhurst Ltd)
This product can't be added to an MCA list.
Stability Information
(Some stability information inherited from generic)
- Stability
-
Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
Protect from light. No stability data in MCAs available.
- Provenance
-
This recommendation is based on the products Zeffix 100mg tablets (GlaxoSmithKline UK) and lamivudine 100mg tablets (Milpharm Aurobindo Pharma - Milpharm Ltd).
- Generic
- Lamivudine
- Formulation
- Lamivudine 100mg tablets
-
Lamivudine
-
Lamivudine 100mg tablets
-
Zeffix 100mg tablets (Dowelhurst Ltd)
-
-